Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) Director Barbara J. Mcneil sold 1,200 shares of the stock on the open market in a transaction dated Friday, May 30th. The stock was sold at an average price of $81.20, for a total value of $97,440.00. Following the sale, the director now directly owns 53,737 shares of the company’s stock, valued at approximately $4,363,444. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Edwards Lifesciences Corp (NYSE:EW) traded down 0.67% on Monday, hitting $80.66. The stock had a trading volume of 894,353 shares. Edwards Lifesciences Corp has a one year low of $60.62 and a one year high of $87.03. The stock’s 50-day moving average is $81.99 and its 200-day moving average is $71.48. The company has a market cap of $8.509 billion and a price-to-earnings ratio of 29.50.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.07. The company had revenue of $522.40 million for the quarter, compared to the consensus estimate of $523.10 million. During the same quarter in the previous year, the company posted $0.72 earnings per share. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp will post $3.16 earnings per share for the current fiscal year.

EW has been the subject of a number of recent research reports. Analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $87.00 to $90.00 in a research note on Thursday, May 22nd. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Edwards Lifesciences Corp from $86.00 to $96.00 in a research note on Wednesday, May 21st. They now have a “buy” rating on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $93.00 in a research note on Friday, May 9th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $81.69.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.